Table 3 Univariate and multivariate analysis for local control and overall survival according to patient and tumor characteristics

Prior CTx^a

2.19 (1.23–3.91)

0.008

2.19 (1.18–4.06)

0.13

Histology (CRC)

1.99 (1.31–3.04)

0.001

1.71 (1.04–2.80)

0.03

Histology (BCa)

0.53 (0.25–1.13)

0.10

0.45 (0.19–1.02)

0.06

Histology (NSCLC)

0.86 (0.26–2.85)

0.81

0.67 (0.19–2.35)

0.54

GTV Volume^c

1.004 (1.002–1.005)

< 0.001

–

PTV Volume^c

1.002 (1.001–1.003)

< 0.001

1.001 (1.00–1.002)

0.003

BED Isocenter^c

0.993 (0.989–0.997)

< 0.001

0.99 (0.98–1.00)

0.002

BED prescription^c

0.72 (0.51–1.01)

0.003

1.00 (0.99–1.01)

0.970

Advanced Motion management^a

0.46 (0.29–0.72)

< 0.001

0.57 (0.33–0.96)

0.04

Before 2003^a

1.50 (1.04–2.16)

0.031

1.02 (0.61–1.70)

0.932

KI^c

0.69 (0.51–0.94)

0.02

0.74 (0.53–0.98)

0.06

Gender

0.80 (0.63–1.01)

0.06

0.76 (0.54–1.06)

0.10

Histology (CRC)

0.61 (0.46–0.79)

< 0.001

0.64 (0.45–0.92)

0.01

Histology (BCa)

0.52 (0.36–0.76)

< 0.001

0.60 (0.36–0.99)

0.05

Histology (NSCLC)

1.42 (0.87–2.33)

0.16

1.14 (0.64–2.07)

0.65

Prior CTx^a

0.91 (0.65–1.27)

0.58

1.17 (0.76–1.80)

0.47

Extrahepatic status^b

0.81 (0.60–1.1)

0.18

0.83 (0.49–1.43)

0.52

Solitary^a

0.73 (0.57–0.92)

0.007

1.12 (0.61–2.03)

0.72

# of liver metastases (1 vs. 2–4)

0.94 (0.72–1.23)

0.65

0.80 (0.52–1.23)

0.32

GTV Volume^c

1.003 (1.002–1.004)

< 0.001

–

PTV Volume^c

1.002 (1.001–1.002)

< 0.001

1.002 (1.001–1.003)

< 0.001

Local recurrence after SBRT^a

0.88 (0.68–1.51)

0.36

0.82 (0.56–1.19)

0.29

BED isocenter^c

0.997 (0.994–1.00)

0.06

1.00 (0.99–1.004)

0.97